TELA Bio Inc (TELA, Financial) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $18.85 million, and the earnings are expected to come in at -$0.41 per share. The full year 2024's revenue is expected to be $74.4 million and the earnings are expected to be -$1.48 per share. More detailed estimate data can be found on the Forecast page.
TELA Bio Inc (TELA, Financial) Estimates Trends
Over the past 90 days, revenue estimates for TELA Bio Inc (TELA) have seen a decrease, moving from $75.22 million to $74.41 million for the full year 2024, and from $95.66 million to $92.77 million for 2025. Conversely, earnings estimates have improved, with projections rising from -$1.62 per share to -$1.48 per share for the full year 2024, and from -$1.15 per share to -$1.02 per share for 2025.
TELA Bio Inc (TELA, Financial) Reported History
In the previous quarter of June 30, 2024, TELA Bio Inc's (TELA) actual revenue was $16.09 million, which missed analysts' revenue expectations of $18.46 million by -12.83%. TELA Bio Inc's (TELA) actual earnings were -$0.51 per share, which missed analysts' earnings expectations of -$0.436 per share by -16.97%. After releasing the results, TELA Bio Inc (TELA) was down by -22.94% in one day.
TELA Bio Inc (TELA, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 5 analysts, the average target price for TELA Bio Inc (TELA) is $10.80 with a high estimate of $14 and a low estimate of $8. The average target implies an upside of 269.86% from the current price of $2.92.
Based on GuruFocus estimates, the estimated GF Value for TELA Bio Inc (TELA, Financial) in one year is $13.61, suggesting an upside of 366.10% from the current price of $2.92.
Based on the consensus recommendation from 5 brokerage firms, TELA Bio Inc's (TELA, Financial) average brokerage recommendation is currently 1.8, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
